<DOC>
	<DOCNO>NCT00585091</DOCNO>
	<brief_summary>There strong evidence clinical trial carvedilol therapy heart failure superior therapy metoprolol . Not carvedilol superior effect lipid profile , insulin sensitivity , renal blood flow , reversal pathologic remodel also use associate few death compare metoprolol . These fact make important carefully define metoprolol carvedilol pharmacologically different . One potential difference α1-AR antagonism . If demonstrate α1-AR effect preserve chronic therapy , α1-AR blockade may important role carvedilol favorably alter natural history heart failure . On hand , demonstrate tolerance α1-AR blockade effect carvedilol decrease time , would unlikely pharmacologic property contributes efficacy carvedilol . In case pharmacologic property , antioxidant activity , would appear important . These result help guide future study CHF AR blockade .</brief_summary>
	<brief_title>The Development Tolerance α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<criteria>1 . Age 18 85 year 2 . Symptomatic heart failure , NYHA class I III 3 . Left ventricular ejection fraction &lt; 0.40 4 . Give write informed consent 1. active myocarditis 2. congenital heart disease 3. uncorrected , hemodynamically significant stenotic valvular disease 4. hypertrophic cardiomyopathy 5 . Asthma obstructive airway disease require bronchodilator 6 . Heart rate &lt; 60 beats/min , supine systolic blood pressure &lt; 85 mm Hg , supine diastolic blood pressure &gt; 90 mm Hg 7 . Uncontrolled Hypertension ( Systolic BP &gt; 140 mmHg , Diastolic BP &gt; 90 mmHg ) . 8 . Sick sinus syndrome , Mobitz type 2 second degree AV block third degree AV block unless control artificial implantable pacemaker 9 . NYHA functional class IV symptoms 10 . Treatment excluded medication ( see Excluded Medications ) 11 . Myocardial infarction coronary artery intervention ( CABG angioplasty ) within three month 12 . Unstable angina pectoris 13 . Presence progressive systemic disease would expect impact patient 's outcome time course study 14 . Uncorrected endocrine disorder include primary aldosteronism , pheochromocytoma , hyperthyroidism , hypothyroidism , brittle type 1 diabetes mellitus 15 . Evidence significant renal disease ( serum creatinine &gt; 2.5 mg/dl ) , hepatic disease ( transaminase level &gt; three fold high laboratory normal ) 16 . Symptomatic peripheral vascular disease 17 . Inability unwillingness cooperate study give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>